Who discovered kisspeptin first?

Danny Welch's group at Penn State College of Medicine identified the KiSS-1 gene in 1996, with J. H. Lee as first author of the paper. Teams including Ohtaki's and Kotani's identified its peptide products and receptor connection in 2001. The human puberty findings followed in 2003, so the credit depends on which discovery is meant.

Was kisspeptin named after Hershey's Kisses?

Yes. Welch and coauthors describe the KISS1 name as a tribute to Hershey, Pennsylvania, where the laboratory was based and where Hershey's Kisses are made. The gene was discovered during cancer research. Its name was already in place before scientists established its role in puberty and began the later sexual-desire studies.

What did the 2003 GPR54 studies discover?

They linked disabling changes in the gene for the kisspeptin receptor to failure of normal puberty. Nicolas de Roux's group and Stephanie Seminara's team reported separate findings in people, with mouse work also supporting the connection. A receptor is a cell's receiving point for a signal; these studies showed why that receiving point mattered.

Who first gave kisspeptin to human volunteers?

Waljit Dhillo and colleagues at Imperial College London reported the landmark 2005 administration study in six healthy men. They compared a 90-minute kisspeptin-54 infusion with saline on separate visits and measured reproductive-hormone changes. This was an early controlled human experiment, not a study of long-term treatment or a home injection schedule.

Does the discovery prove kisspeptin treats low desire or infertility?

The discovery alone does not establish a treatment benefit. Later studies separately tested egg maturation during supervised fertility treatment and short-term responses to sexual cues in people distressed by low desire. Those experiments used specific peptide forms and delivery methods. Their results cannot establish lasting benefits or safety for every compounded formulation.

Who Discovered Kisspeptin? The People Behind It

Danny Welch's team at Penn State College of Medicine made the first discovery in 1996, while studying how melanoma, a type of skin cancer, spreads. They found KiSS-1, the gene that carries the instructions for kisspeptin. Asking who discovered kisspeptin also brings in the teams that identified its peptide products in 2001 and its role in puberty in 2003. A peptide is a short chain of amino acids, the body's protein building blocks.

That distinction explains the different names and dates attached to this story. Each group answered a different question.

Who discovered kisspeptin's gene, and what were they looking for?

Welch's group worked at Penn State's College of Medicine in Hershey, Pennsylvania. Their question was about metastasis: cancer spreading from its original site to other parts of the body.

The team compared human melanoma cells that spread readily with altered cells that did not. They identified a gene active in the less-spreading cells and called it KiSS-1. Putting that gene into melanoma cells reduced their ability to spread in the experiments.

J. H. Lee was first author and Danny R. Welch was senior author of the original paper, published December 4, 1996, in the Journal of the National Cancer Institute. Several colleagues shared the work and the authorship.

This was a finding about cancer cells and experimental models. Nobody had tested a kisspeptin injection as a treatment for a person's cancer. The reproductive-hormone story had not yet emerged.

Why is kisspeptin called kisspeptin?

The chocolate connection is real. In a 2020 account coauthored by Welch, the researchers explain that KISS1 honored the town where they found it: Hershey, home of Hershey's Kisses.

The next question was what the gene actually made. In 2001, Tetsuya Ohtaki's team at Takeda in Tsukuba, Japan, isolated a 54-building-block peptide from human placenta, the organ that supports a pregnancy. They named it metastin, reflecting the cancer work. Their Nature paper connected it to a receptor, a docking point on a cell that receives a signal.

That same year, M. Kotani and colleagues at the IRIBHN research institute in Brussels identified related peptides that activated GPR54, now called the kisspeptin receptor. Their Journal of Biological Chemistry paper called the peptides kisspeptins. These were separate contributions to identifying the messenger and the cell machinery that responds to it.

The GPR54 discovery in 2003 changed the question

Two groups then approached the system through people whose puberty had not developed normally.

Nicolas de Roux and colleagues at INSERM and Hôpital de Bicêtre in France studied a family with five affected siblings. All five carried a disabling change in the gene for GPR54. Their 2003 PNAS paper connected that change to insufficient reproductive-hormone signaling.

Separately, Stephanie Seminara and an international team, including researchers at Massachusetts General Hospital and Cambridge, found damaging changes in the same gene. Their 2003 New England Journal of Medicine paper combined findings in people with experiments in mice lacking the receptor.

The plain finding was striking: when this receiving system did not work, normal puberty could fail to start. Calling kisspeptin a switch for reproduction comes from that evidence. It doesn't mean one molecule explains every fertility problem.

Waljit Dhillo's team brought the question into human studies

At Imperial College London, Waljit Dhillo and colleagues asked whether giving kisspeptin would change reproductive-hormone levels in volunteers.

Their 2005 Journal of Clinical Endocrinology & Metabolism study gave six healthy men a 90-minute infusion into a vein. Each man also received saline, a saltwater comparison, on another visit. Reproductive-hormone levels rose during the kisspeptin condition. This was early evidence that an administered peptide could prompt a human response.

In 2011, Channa Jayasena and colleagues studied the shorter kisspeptin-10 in men and women. Responses differed with sex and menstrual-cycle stage; they also measured how quickly it left human blood. What kisspeptin does explains the signaling and those timing measurements.

Recognition followed: the Society for Endocrinology awarded Dhillo its 2015 Society for Endocrinology Medal for work on hormone control of appetite and reproductive function.

What came of it: fertility and sexual-desire studies

Jayasena, Ali Abbara, Dhillo and colleagues tested kisspeptin-54 during IVF, fertility treatment in which eggs are fertilized outside the body. Their 2014 Journal of Clinical Investigation trial enrolled 53 women and studied whether it could trigger the final step in egg maturation. A 2015 follow-up led by Abbara enrolled 60 women at high risk of the ovaries overreacting to fertility treatment. These were supervised fertility protocols.

Later, Imperial researchers including Layla Thurston, Edouard Mills and Alexander Comninos studied hypoactive sexual desire disorder, persistently low desire that causes distress. Trials published in 2022 in women and 2023 in men, both in JAMA Network Open, had 32 participants complete each study. Kisspeptin-54 changed responses to sexual cues during brief infusions. These findings did not establish lasting improvement with home treatment.

PT-141, also called bremelanotide, belongs in a sexual-health discussion too, but it acts on a different family of cell receptors. It is a separate medicine with its own evidence; the kisspeptin discovery does not establish what PT-141 will do.

The researchers are still working on duration

As of September 10, 2026, the day this article was written, an August 3, 2026 publication by Arthur Yeung and colleagues at Imperial had extended the human story to repeated kisspeptin-10 delivery. The European Journal of Endocrinology study recruited 15 healthy men across three experiments, with seven in the 12-day experiment. Delivery under the skin with a daily break sustained reproductive-hormone responses through day 12. That adds information about timing, without establishing a long-term treatment benefit.

The kisspeptin and testosterone article covers the hormone results. The distinction between the peptide forms also matters: kisspeptin-10 and kisspeptin-54 have different lengths and exposure patterns in these studies.

What the discovery did not settle

Finding a necessary signal is different from knowing when adding more will help. The cancer experiments, puberty genetics, fertility protocols and desire studies each answer their own question. None establishes a universal kisspeptin dose or proves that a compounded preparation reproduces a trial's results.

As of September 10, 2026, the day this article was written, FDA's ingredient-nomination list, marked “Updated May 14, 2026,” still placed kisspeptin-10 in Category 2, its group for substances raising significant safety risks. Kisspeptin is not FDA-approved, and the compounded formulation offered here is not FDA-approved; the agency's October 29, 2024 review documents kisspeptin-10's lack of an approved product. A licensed provider may still prescribe a compounded formulation where appropriate; that decision is between the patient and doctor.

Where the prescription conversation fits

The history gives a provider something concrete to discuss: which form was studied, in whom, and what was actually measured. A person's symptoms, medications, hormone results and reproductive plans determine whether that evidence fits their situation.

At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies. If prescribed, a licensed U.S. compounding pharmacy prepares the medication, and the prescriber sets the dose and follow-up. The research informs that conversation; it does not make the decision for either person.